Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TRPV6 | Q9H1D0 | 3/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25672740 | 0.92 | MEN1 (0.36) | MEN1KMT2ATRPV6OPRL1OPRM1 | |
| SCHEMBL25594480 | 0.91 | MEN1 (0.47) | MEN1KMT2ATRPV6OPRL1OPRM1 | |
| SCHEMBL18133869 | 0.89 | MEN1 (0.39) | MEN1KMT2ATRPV6OPRL1OPRM1 | |
| SCHEMBL13154267 | 0.89 | SIGMAR1 (0.40) | MEN1KMT2ATRPV6OPRL1OPRM1 | |
| SCHEMBL10433619 | 0.89 | MEN1 (0.46) | MEN1KMT2ATRPV6OPRL1OPRM1 | |
| SCHEMBL803132 | 0.89 | MEN1 (0.45) | MEN1KMT2ATRPV6OPRL1OPRM1 | |
| SCHEMBL25595993 | 0.88 | HTR6 (0.39) | MEN1KMT2ASIGMAR1CYP2D6CYP2C19 | |
| SCHEMBL25046264 | 0.87 | MEN1 (0.49) | MEN1KMT2ATRPV6OPRL1OPRM1 | |
| SCHEMBL10433611 | 0.87 | MEN1 (0.45) | MEN1KMT2ATRPV6OPRL1OPRM1 | |
| SCHEMBL22570042 | 0.87 | MEN1 (0.49) | MEN1KMT2ATRPV6OPRL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES LIMITED | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | P2RY1, P2RX7, P2RX1 | MEN1 3931/4885KMT2A 4583/4885TRPV6 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.